Positron emission tomography: imaging and quantification of neurotransporter availability
about
sameAs
Insight into the Molecular Imaging of Alzheimer's DiseaseA philosophy for CNS radiotracer designRecent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment.Synthesis, fluorine-18 radiolabeling, and biological evaluation of N-((E)-4-fluorobut-2-en-1-yl)-2beta-carbomethoxy-3beta-(4'-halophenyl)nortropanes: candidate radioligands for in vivo imaging of the brain dopamine transporter with positron emissionEffects of overexpression of copper-zinc and manganese superoxide dismutases, catalase, and thioredoxin reductase genes on longevity in Drosophila melanogaster.Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia.Central serotonin transporter levels are associated with stress hormone response and anxiety.Tomography of epidermal growth factor receptor binding to fluorescent Affibody in vivo studied with magnetic resonance guided fluorescence recovery in varying orthotopic glioma sizes.Synthesis, F-18 radiolabeling, and microPET evaluation of 3-(2,4-dichlorophenyl)-N-alkyl-N-fluoroalkyl-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amines as ligands of the corticotropin-releasing factor type-1 (CRF1) receptor.The role of emission tomography in pharmacokinetic and pharmacodynamic studies in clinical psychopharmacology.Imaging of opioid receptors in the central nervous systemVarenicline-Induced Elevation of Dopamine in Smokers: A Preliminary [(11)C]-(+)-PHNO PET Study.Synthesis, radiosynthesis, and biological evaluation of fluorine-18-labeled 2beta-carbo(fluoroalkoxy)-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomGlia and immune cell signaling in bipolar disorder: insights from neuropharmacology and molecular imaging to clinical application.Fluorine-18 Radiolabeled PET Tracers for Imaging Monoamine Transporters: Dopamine, Serotonin, and Norepinephrine.Evolution of Deep Brain Stimulation: Human Electrometer and Smart Devices Supporting the Next Generation of Therapy.Molecular Neurobiology of Depression: PET Findings on the Elusive Correlation with Symptom Severity.PET imaging for receptor occupancy: meditations on calculation and simplification.Tropane-derived (11) C-labelled and (18) F-labelled DAT ligands.Development of (18)F-labeled radiotracers for neuroreceptor imaging with positron emission tomographySynthesis, binding affinity, radiolabeling, and microPET evaluation of 4-(2-substituted-4-substituted)-8-(dialkylamino)-6-methyl-1-substituted-3,4-dihydropyrido[2,3-b]pyrazin-2(1H)-ones as ligands for brain corticotropin-releasing factor type-1 (CRFThe influence of genetic variants on striatal dopamine transporter and D2 receptor binding after TBI.Test-retest reliability of the SERT imaging agent [(11)C]HOMADAM in healthy humans.Investigating the effects of norepinephrine α1 receptor blockade on dopamine levels: A pilot PET study with [11 C]-(+)-PHNO in controls.Detecting a dexmedetomidine-evoked reduction of noradrenaline release in the human brain with the alpha2C-adrenoceptor PET ligand [11C]ORM-13070.Investigation of the influence of sampling schemes on quantitative dynamic fluorescence imaging.
P2860
Q26765945-2BD1998B-13AE-411A-BFD4-4F95C2646883Q26853140-BB1F6A01-4F93-4342-98DA-0ED0BB80B8F9Q33556068-0D3641BA-D3C5-4000-BDBD-09FF5C1836E1Q33623987-D7FA7143-4827-4D7C-86F1-BD647A503CC5Q34196418-7EB86BED-F7F4-493D-8EBC-66E2DC3632ADQ34272454-4F506586-8BC9-4A59-AB89-68849C2B7681Q34441012-12462DC3-CF2C-40C6-9D6C-1AE112743BAEQ35049632-DC1E1146-F136-4661-B497-F206713E4D3EQ35894035-217AD291-820C-425E-AF93-0D48684FA7B0Q36511717-F1CE313E-5A7A-45B0-BC8B-2CEB9C719B63Q36633126-124DC876-E53E-4DA8-94D8-9FFB713E5D44Q36798993-C1BB6046-5B2E-42E1-B339-E492587F55B2Q37156598-D4F12CFF-2EE6-4F2E-A551-EB192A5B87C9Q37526428-7C7C6C62-1767-4CE4-BC1B-4BA309F87F45Q37706110-6AF87FA6-A871-41B0-8337-7345583EE8A4Q37775521-9024BC65-C4CB-44C1-9AB9-E00F99B650A9Q38086422-96CF82BE-837A-4112-A5C3-EF64FA0405E5Q38095925-A761389F-F3F0-4F7B-B2E5-45082E3B5FEDQ38166969-53877D2D-13FB-4BC9-BCCB-97EDEBE7A36BQ38244707-D6408217-B0F7-4D18-9E87-E100A456F695Q38828768-9F046B8F-2E7F-4FA6-B1D7-55D6B2ADD8C3Q39188526-5B83D813-988D-42A4-8F37-AA0B8D1829AAQ47568558-A3E422FE-1C1E-4D88-A39D-DF537EDACA3DQ47792463-67AA0F6F-BF07-4734-A131-F214BD8EE060Q52146902-723A2978-1EBA-443F-A435-9F22A9C1D098Q54940302-D9119A0F-A441-467E-AEF6-53EA2D53DB81
P2860
Positron emission tomography: imaging and quantification of neurotransporter availability
description
2002 nî lūn-bûn
@nan
2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Positron emission tomography: imaging and quantification of neurotransporter availability
@ast
Positron emission tomography: imaging and quantification of neurotransporter availability
@en
Positron emission tomography: imaging and quantification of neurotransporter availability
@nl
type
label
Positron emission tomography: imaging and quantification of neurotransporter availability
@ast
Positron emission tomography: imaging and quantification of neurotransporter availability
@en
Positron emission tomography: imaging and quantification of neurotransporter availability
@nl
prefLabel
Positron emission tomography: imaging and quantification of neurotransporter availability
@ast
Positron emission tomography: imaging and quantification of neurotransporter availability
@en
Positron emission tomography: imaging and quantification of neurotransporter availability
@nl
P2093
P1433
P1476
Positron emission tomography: imaging and quantification of neurotransporter availability
@en
P2093
Marc Laruelle
Mark Slifstein
Yiyun Huang
P304
P356
10.1016/S1046-2023(02)00085-3
P407
P577
2002-07-01T00:00:00Z